Page 8 - Commodore Capital News Today

Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Rating) shares reached a new 52-week high on Monday . The company traded as high as $10.98 and last traded at $10.86, with a volume of 44021 shares trading hands. The stock had previously closed at $10.53. Wall Street Analyst Weigh In A number of research analysts recently […]

Shares of Ambrx Biopharma Inc. (NYSE:AMAM – Get Rating) shot up 6.2% on Tuesday . The company traded as high as $14.96 and last traded at $14.88. 257,564 shares were traded during trading, a decline of 92% from the average session volume of 3,041,147 shares. The stock had previously closed at $14.01. Wall Street Analyst […]

Jefferies Financial Group upgraded shares of Allakos (NASDAQ:ALLK – Get Rating) from a hold rating to a buy rating in a research note released on Thursday, The Fly reports. Jefferies Financial Group currently has $9.00 price target on the stock, up from their prior price target of $6.00. Other analysts have also issued research reports […]

Lifesci Capital lowered shares of BELLUS Health (NASDAQ:BLU – Get Rating) from an outperform rating to a market perform rating in a report released on Tuesday morning, Marketbeat.com reports. Several other analysts have also recently weighed in on the company. Evercore ISI cut BELLUS Health to an outperform rating in a report on Tuesday. HC […]

EQS-News: ABIVAX / Key word: Annual Results Abivax reports 2022 financial results and operations update 19.04.2023 / 21:00 CET/CEST The issuer is solely responsible for the... | April 19, 2023

Obefazimod global pivotal phase 3 program (ABTECT program) in moderate to severe ulcerative colitis (UC) early enrollment progressing according to planAbivax reports promising Phase 2b maintenance results

19.04.2023 - EQS-News: ABIVAX / Key word(s): Annual Results Abivax reports 2022 financial results and operations update 19.04.2023 / 21:00 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax reports 2022 financial results and ...

EQS-News: ABIVAX / Key word(s): Annual ResultsAbivax reports 2022 financial results and operations update 19.04.2023 / 21:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Abivax reports 2022 financial results and operations update Obefazimod global pivotal phase 3 program (ABTECT...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating) has earned an average recommendation of “Moderate Buy” from the eleven analysts that are currently covering the company, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price objective among […]

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating) has been given a consensus rating of “Moderate Buy” by the eleven brokerages that are presently covering the company, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year price […]